Misplaced Pages

Simnotrelvir/ritonavir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Simnotrelvir) Antiviral combination medication

Pharmaceutical compound
Simnotrelvir/ritonavir
Chemical structures of simnotrelvir (top) and ritonavir (bottom)
Combination of
SimnotrelvirSARS-CoV-2 3CL inhibitor
RitonavirProtease inhibitor
Clinical data
Trade names先诺欣 (Xiannuoxin)
Pregnancy
category
  • Contraindicated (CN)
Routes of
administration		Oral
Legal status
Legal status
  • Rx in China
Pharmaceutical compound
Simnotrelvir
Clinical data
Other namesSIM0417, SSD8432
Routes of
administration		Oral
Drug classSARS-CoV-2 3CL inhibitor
Legal status
Legal status
  • Not approved on its own
Pharmacokinetic data
Protein binding72.5%
Metabolismhepatic (CYP3A)
Elimination half-life3.1 h; 4.1 h with ritonavir
Excretionurine (55.4%), feces (36.7%)
Identifiers
IUPAC name
  • (8S)-N-ethyl]-7-butanoyl]-1,4-dithia-7-azaspirononane-8-carboxamide
PubChem CID
Chemical and physical data
FormulaC22H30F3N5O4S2
Molar mass549.63 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C)(C(=O)N1CC2(C1C(=O)N(C3CCNC3=O)C#N)SCCS2)NC(=O)C(F)(F)F
InChI
  • InChI=InChI=1S/C22H30F3N5O4S2/c1-20(2,3)15(29-19(34)22(23,24)25)18(33)30-11-21(35-6-7-36-21)9-14(30)17(32)28-13(10-26)8-12-4-5-27-16(12)31/h12-15H,4-9,11H2,1-3H3,(H,27,31)(H,28,32)(H,29,34)/t12-,13-,14-,15+/m0/s1
  • Key:LQBRGTAIBBFUJJ-ZQDZILKHSA-N

Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CL, and ritonavir, a CYP3A inhibitor.

It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. Results for the phase Ib trial are available. In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.

See also

References

  1. ^ Simcere (January 28, 2023). "先诺欣 [先诺特韦片/利托那韦片组合包装 Simnotrelvir Tablets/Ritonavir Tablets（co-packaged）]". Dxy.cn package insert database (in Chinese (China)). Retrieved 2 October 2023.
  2. Zhu KW (September 2023). "Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134. PMC 10496140. PMID 37705591.
  3. Wang Q, Chen G, He J, Li J, Xiong M, Su H, et al. (May 2023). "Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease". International Journal of Molecular Sciences. 24 (10): 8633. doi:10.3390/ijms24108633. PMC 10218254. PMID 37239980.
  4. "China approves two oral drugs to treat COVID-19". bioworld.com. January 30, 2023.
  5. Wang F, Xiao W, Tang Y, Cao M, Shu D, Asakawa T, et al. (September 2023). "Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial". The Lancet Regional Health. Western Pacific. 38: 100835. doi:10.1016/j.lanwpc.2023.100835. PMC 10362366. PMID 37484496.
  6. Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, et al. (2024-01-18). "Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19". New England Journal of Medicine. 390 (3): 230–241. doi:10.1056/NEJMoa2301425. PMC 11156186. PMID 38231624. S2CID 267030019.

External links

Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Categories: